Vivos Inc (RDGL)

[chereb19]

Planning manufacturing capability ahead of clinical trials is normal regulatory practice. Applications require documented production methods, quality controls, and validation steps so the agency knows the material can be produced consistently and safely before any dosing occurs. Mentioning facilities or licensing in that context is part of preparation, not commercialization.